Skip Navigation LinksHome > January 2013 - Volume 47 - Issue 1 > The Use of Probiotics in Helicobacter pylori Eradication The...
Journal of Clinical Gastroenterology:
doi: 10.1097/MCG.0b013e3182702dbc
Editorials

The Use of Probiotics in Helicobacter pylori Eradication Therapy

Medeiros, José A. MD, PhD*; Pereira, Marta-Isabel MD*,†

Free Access
Article Outline
Collapse Box

Author Information

*Institute of Physiology, Faculty of Medicine, University of Coimbra

Department of Clinical Hematology, Coimbra University Hospitals, Portugal

The authors declare that they have nothing to disclose.

Reprints: José A. Medeiros, MD, PhD, Rua do Carmo, no: 54, 4V, 3000-098 Coimbra, Portugal (e-mail: jmedeiros@fmed.uc.pt).

Helicobacter pylori infection in humans is associated with a spectrum of gastroenterologic and hematologic diseases including chronic gastritis, peptic ulcers, gastric adenocarcinoma, gastric mucosa–associated lymphoid tissue lymphoma, sideropenic anemia, and primary immune thrombocytopenia. Successful eradication of the bacterium is a major component in the treatment of these conditions.

However, despite the cost of therapy, the rates of eradication after triple therapies are decreasing, with standard amoxicillin plus clarithromycin-based triple therapy achieving eradication rates of only about 75% in many series, albeit with an apparent geographic variation, in agreement with differing patterns of antibiotic resistance throughout the world.1–3 Quadruple second-line therapy has, likewise, resulted in unsatisfactory eradication rates.

Although unsuccessful eradication can be due to increasing antimicrobial resistance, an additional important contributor is the high incidence of treatment-related side effects (including diarrhea, nausea, epigastric discomfort, and dysgeusia with a metallic taste), determining low compliance, and, consequently, incomplete therapy. Many of these gastrointestinal effects result from the modification of the ecologic equilibrium of intestinal microbiota due to the antibiotics.4

The identification of alternative therapeutic strategies to overcome these limitations is a pressing issue. Although altering the duration of treatment or the choice of first-line antibiotics can target resistance patterns, lack of adherence to treatment because of adverse events has been addressed mostly through the addition of probiotics to eradication regimens, in an attempt to reestablish the gastrointestinal microbial equilibrium.

Probiotics are live nonpathogenic microbial food products or supplements whose interaction with the host can benefit the health status of the latter, mostly through the modulation of the balance of its microflora, although direct antimicrobial effects have been described by some groups.5

Probiotic bacteria are able to survive in the gastrointestinal tract despite the administration of antimicrobial eradication regimens, as shown by the recovery of probiotics from the feces of treated patients.6 In addition, it has been demonstrated that the supplementation of eradication protocols with probiotics does impact the intestinal microflora. Whereas triple therapy results in significant increases in the facultative anerobe component of the microflora after the start of treatment, the addition of Lactobacillus acidophilus and Bifidobacterium bifidum midtreatment reverts this increase back to starting levels, and the addition from the start maintains a stable facultative anerobe population throughout treatment and follow-up.7 Similarly, although the percentage of bifidobacteria in anerobes in the stool is significantly decreased by triple therapy, supplementation with an L. acidophilus-containing and B. lactis-containing yogurt is able to restore the population of bifidobacteria to pretreatment levels.8

Apart from the modification of gastrointestinal microflora, which can be harnessed to reduce treatment-associated side effects, probiotics have also been shown to exert direct inhibitory effects on H. pylori in both in vitro and in vivo animal models, with the potential to improve eradication rates. These effects have been demonstrated for several species of probiotics, including L. acidophilus, L. salivarius, L. rhamnosus, and B. bifidum, among others.9–11

Proposed mechanisms underlying the beneficial interaction between probiotics and H. pylori, and the modulation of the colonization of the gastric mucosa by the latter, include the production of lactic acid with H. pylori inhibition because of decreasing gastric pH; the direct killing of H. pylori through secreted metabolites with antimicrobial properties, including bacteriocins, autolysins, and organic acids; the interference with H. pylori adhesion to epithelial cells, both through the secretion of antimicrobial molecules and through direct competition for adhesion; and the ability to reduce H. pylori-induced gastritis through the stabilization of the mucosal barrier, the secretion of mucins, and the modulation of the host immune response to the infection. These mechanisms have been amply reviewed in the literature over the past decade.10,12–16

Despite this theoretical foundation justifying the use of probiotics as adjuncts to eradication therapy, published clinical trial data have yielded dissonant results, and probiotic supplementation remains a controversial issue.

In fact, the definition of “probiotic” includes a wide range of microbial species, an aspect that can partially help explain the contradictory results obtained in different trials, because of the use of distinct probiotic strain combinations. The method, dose, and timing of supplementation, likewise, vary markedly among studies, with some authors on one end of the spectrum using multistrain milk-based fermented preparations (including yogurt and kefir) and on the other end using pure single-strain supplementation in capsule form.17,18 Whereas some authors have reported starting probiotics as much as 4 weeks before eradication, few have restricted supplementation for the duration of the eradication therapy, and others prolong it for as long as 4 or even 8 weeks after therapy.8,18–20

The lack of protocol standardization is not the only problem, and difficulties in interpretation of the various results are compounded by the type of analysis performed and the outcomes that are measured. Whereas some groups have primarily looked at the incidence or severity of side effects, others have focused on eradication rates; in the latter case, results can additionally be reported either through an intention-to-treat analysis or a per-protocol analysis. A final problem contained in the current literature is the number of pilot studies and trials with small sample sizes, which might not be adequately powered to find small differences in eradication rates or in the frequency of individual adverse events.

Despite the contradictory results, some considerations can be made regarding the existing literature. Although direct anti-H. pylori effects have been described, the present data do not appear to support the isolated use of probiotics as an alternative to eradication therapy, as no trial has been able to conclusively demonstrate successful eradication of H. pylori infection by probiotic treatment alone,13,16 although a recent pilot study reports that treatment with an association of 8 species of probiotics resulted in H. pylori negativity in 13 of 40 H. pylori-positive dyspeptic patients.21

In fact, in vitro results do not seem to translate to in vivo efficacy, as shown with a multistrain yogurt containing L. acidophilus, L. casei, L. bulgaricus, and Streptococcus thermophilus strains with in vitro inhibitory effects on H. pylori, which did not successfully eradicate H. pylori in asymptomatic women.22

Nevertheless, probiotics have been shown to be able to reduce the gastric load of the pathogen, theoretically facilitating eradication by subsequent antimicrobial regimens.12 However, although L. reuteri was able to reduce the intragastric H. pylori load before sequential eradication treatment—with a significant reduction in dyspepsia—eradication rates were not affected.23

Systematic reviews of the literature have shown that various probiotic species (including Lactobacillus spp., Bifidobacterium spp., Saccharomyces spp., and Bacillus spp.20,24) can help diminish eradication-related side effects, including diarrhea, nausea, dyspepsia, and dysgeusia, increasing tolerability and, therefore, compliance. It has been postulated that it is this increase in the number of patients completing the therapy as prescribed that could, in turn, lead to higher eradication rates.16,25,26 However, a series of patients treated with sequential therapy demonstrated that, although the addition of probiotics increased compliance through the decrease in treatment-associated symptoms, there was no effect on eradication rates.27 In contrast, a meta-analysis of 14 randomized trials comparing probiotic supplementation to placebo or no-intervention found that probiotics increased eradication rates and decreased antibiotic-related side effects.28 One of the main limitations of this analysis was the inclusion of several different probiotics, which could be unequally effective.

Considering lactobacilli, data remain contradictory. In 2009 a meta-analysis of 8 randomized trials on the supplementation of triple therapy with lactobacilli showed a benefit in eradication rates (by an intention-to-treat analysis), with a decrease in diarrhea, bloating, and dysgeusia.9 This is supported by the recent report that the eradication rate with second-line levofloxacin-based therapy was significantly improved by supplementation with L. reuteri, with a decrease in the incidence of nausea and diarrhea.4 L. reuteri has also been reported to decrease therapy-associated side effects in children undergoing sequential therapy, both during eradication therapy and at follow-up.29 Nevertheless, a comparison of standard 7-day therapy, standard 7-day therapy plus L. reuteri supplementation, and standard 7- or 14-day therapy plus a high-concentration probiotic mixture achieved statistically similar eradication rates of <80% for all groups, with no differences in the incidence of side effects.1

Similarly, in our own series, in 2011, we found that the addition of L. acidophilus to standard triple therapy did not influence eradication rates.18 However, a combination of L. acidophilus with L. rhamnosus was shown to increase the eradication rate of standard triple therapy.30 In contrast, although the addition of L. rhamnosus to triple therapy, in adults, decreased the incidence of diarrhea, nausea, and dysgeusia, and increased treatment tolerability, in pediatric patients it did not significantly alter the eradication rate or side effects.31,32 In patients resistant to first-line therapy, the supplementation of quadruple therapy with L. casei was able to reduce treatment-associated side effects.33

The bifidobacteria have also been the subject of trials in eradication therapy. Although the addition of B. animalis-containing yogurt to standard triple therapy did not improve eradication rates, it was found to reduce the incidence of stomatitis and of constipation.14 The majority of trials analyzing bifidobacteria, however, have used associations with lactobacilli, especially in milk products. In fact, yogurt containing live L. acidophilus and B. lactis was associated with a significantly reduced mean number of days with antibiotic-associated diarrhea (but not with its frequency), compared with the same yogurt with killed bacteria, and with milk acidified with lactic acid, supporting an active role for the live bacteria.19 It was shown that the twice-daily ingestion of L. acidophilus and B. lactis-containing yogurt over a period of 6 weeks decreased the gastric H. pylori bacterial load, when compared with a milk-based placebo; nevertheless, in vitro, only the Bifidobacterium strain showed H. pylori-inhibitory effects.34 The supplementation of triple therapy with L. acidophilus and B. lactis-containing yogurt increased the eradication rate by intention-to-treat analysis; by per-protocol analysis, the eradication rate was identical to the no-intervention group, suggesting that it improves eradication by increasing compliance and the number of patients who effectively complete the treatment protocol.8 However, when used as pretreatment to second-line quadruple therapy, this yogurt also significantly decreased the gastric H. pylori load, increasing the eradication rate, compared with quadruple therapy alone.35 Other alternative lactobacilli-bifidobacteria associations have also been reported to increase the eradication rate of standard triple therapy.36

Another group of studies has described positive results with Saccharomyces boulardii, which was shown in a meta-analysis of 5 randomized trials to significantly increase the eradication rate of standard triple therapy and decrease the incidence of therapy-related side effects, most notably diarrhea.37 Even dissenting trials that suggested it did not improve the eradication rate of standard 14-day eradication therapy found that the incidence of diarrhea and of epigastric discomfort were reduced, as were posttreatment dyspepsia scores, irrespective of H. pylori status.38 One large study suggested that S. boulardii increased eradication rates as a consequence of reduced side effects improved compliance and completion of therapy (with identical eradication rates on a per-protocol analysis).39 The supplementation with S. boulardii is associated with no additional side effects, demonstrating its safety.40

Despite the increase in eradication rates when S. boulardii is added to standard triple therapy, it has been shown that standard amoxicillin-clarithromycin-based triple therapy plus S. boulardii still has worse results in terms of eradication rates than probiotic-free levofloxacin-based triple or sequential therapies.41

Although trials comparing different probiotics are rare, one such study found that the supplementation of triple therapy with L. rhamnosus, with lactobacilli plus bifidobacteria, or with S. boulardii all resulted in identically lowered incidences of diarrhea and dysgeusia compared with the placebo group, with no effects on compliance or eradication rates.42

One final group of studies has looked at more heterogenous preparations of probiotics. A randomized comparison of standard triple therapy with kefir (a fermented milk-based product) compared with triple therapy plus a milk-based placebo found an increased eradication rate with kefir, with a decrease in the frequency and severity of side effects.17 A previous systematic review of 10 randomized trials analyzing the addition of fermented milk-based probiotic preparations to eradication protocols had found a benefit for the treatment group in eradication rates by intention-to-treat analysis, although with a heterogenous effect in the reduction of treatment-related adverse events.43

A trial of standard triple therapy with a multistrain yogurt preparation containing L. acidophilus, L. casei, B. longum, and S. thermophilus found comparable eradication rates to the control group by intention-to-treat analysis, but higher rates by per-protocol analysis. Contrary to all other studies, the frequency of side effects was higher in the yogurt group, while the severity was identical in both groups.44 The addition of a similar yogurt preparation to second-line moxifloxacin-amoxicillin-based therapy did not affect either eradication rates or the incidence of side effects.45

The data presented above justify the need for a new meta-analysis, as has been performed by Wang et al46 in the present issue of this journal, and which addresses the limitation of the use of different probiotic formulations by the different trials, by including only those studies using probiotic preparations containing both lactobacilli and bifidobacteria. This combination not only approximates commercially available foodstuffs, including yogurts, but has also been associated with a wider number of trials and with less contradictory results, as shown above. Moreover, as unsuccessful eradication is a problem for both first-line and second-line therapies, the inclusion of both types of study in the present meta-analysis overcomes what can be perceived as a limitation of previous meta-analyses,46 which focused solely on first-line eradication, whereas it is patients in second-line therapy who probably will benefit more from adjuncts to therapy, because of their primary refractoriness.

The authors found that preparations containing both lactobacilli and bifidobacteria were able to improve eradication rates and decrease the incidence of side effects in adults regardless of ethnicity and independently of the eradication protocol used.46 The putative relationship between improved tolerance, increased compliance, and eradication success was, however, not analyzed; therefore the question remains whether there is a direct effect of this combination of probiotics on H. pylori, or whether the benefit is a consequence of the ability to complete treatment as planned.

Considering that the risk-benefit ratio is positive because of their favorable safety profiles,47 the final decision to add a probiotic to eradication therapy should weigh the clinical trial results against patient-specific aspects. It has previously been suggested that the usefulness of probiotic adjunct therapy is particularly relevant in patients with a history of gastrointestinal intolerance to antibiotic treatment.25 Other factors to take into account should include patient preference (including a taste for yogurt, kefir, or other fermented milk products) and the probability that supplementation in capsule form could lead to decreased compliance due to the greater number of daily pills to ingest or to a cumbersome treatment protocol that is incompatible with the patient’s lifestyle. The additional cost to therapy should also be discussed with the patient and analyzed against the loss of productivity or of work hours because of treatment-associated side effects, most notably diarrhea and epigastric discomfort.

One final aspect to weigh into the clinical decision are the results currently obtained with sequential therapy, with improved tolerability due to the shorter course of the individual antibiotics, and with eradication rates of over 92% with first-line therapy and over 97% after second-line rescue, which are higher than those reported for probiotic-supplemented standard triple therapy.48

Back to Top | Article Outline

REFERENCES

1. Scaccianoce G, Zullo A, Hassan C, et al. Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci. 2008;12:251–256

2. de Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol. 2007;102:951–956

3. O’Connor A, Gisbert JP, McNamara D, et al. Treatment of Helicobacter pylori infection 2011. Helicobacter. 2011;16(suppl 1):53–58

4. Ojetti V, Bruno G, Ainora ME, et al. Impact of lactobacillus reuteri supplementation on anti-Helicobacter pylori levofloxacin-based second-line therapy. Gastroenterol Res Pract. 2012;2012:article ID 740381

5. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989;66:365–378

6. Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther. 2005;21:1263–1272

7. Madden JAJ, Plummer SF, Tang J, et al. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol. 2005;5:1091–1097

8. Sheu B-S, Wu J-J, Lo C-Y, et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 2002;16:1669–1675

9. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009;14:97–107

10. Canducci F, Cremonini F, Armuzzi A, et al. Probiotics and Helicobacter pylori eradication. Dig Liver Dis. 2002;34(suppl 2):S81–S83

11. Chenoll E, Casinos B, Bataller E, et al. Novel probiotic Bifidobacterium bifidum CECT 7366 strain active against the pathogenic bacterium Helicobacter pylori. Appl Environ Microbiol. 2011;77:1335–1343

12. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther. 2006;23:1077–1086

13. Lesbros-Pantoflickova D, Corthésy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr. 2007;137(suppl 2):812S–818SS

14. Yaşar B, Abut E, Kayadibi H, et al. Efficacy of probiotics in Helicobacter pylori eradication therapy. Turk J Gastroenterol. 2010;21:212–217

15. Felley C, Michetti P. Probiotics and Helicobacter pylori. Best Pract Res Clin Gastroenterol. 2003;17:785–791

16. Franceschi F, Cazzato A, Nista EC, et al. Role of probiotics in patients with Helicobacter pylori infection. Helicobacter. 2007;12(suppl 2):59–63

17. Bekar O, Yilmaz Y, Gulten M. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J Med Food. 2011;14:344–347

18. Medeiros JADS, Gonçalves TMFO, Boyanova L, et al. Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis. 2011;30:555–559

19. de Vrese M, Kristen H, Rautenberg P, et al. Probiotic lactobacilli and bifidobacteria in a fermented milk product with added fruit preparation reduce antibiotic associated diarrhea and Helicobacter pylori activity. J Dairy Res. 2011;78:396–403

20. Park SK, Park DI, Choi JS, et al. The effect of probiotics on Helicobacter pylori eradication. Hepatogastroenterology. 2007;54:2032–2036

21. Rosania R, Minenna MF, Giorgio F, et al. Probiotic multistrain treatment may eradicate Helicobacter pylori from the stomach of dyspeptics: a placebo-controlled pilot study. Inflamm Allergy Drug Targets. 2012;11:244–249

22. Wendakoon CN, Thomson ABR, Ozimek L. Lack of therapeutic effect of a specially designed yogurt for the eradication of Helicobacter pylori infection. Digestion. 2002;65:16–20

23. Francavilla R, Lionetti E, Castellaneta SP, et al. Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study. Helicobacter. 2008;13:127–134

24. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther. 2004;20:1181–1188

25. Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother. 2011;45:960–966

26. Jonkers D, Stockbrügger R. Review article: Probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther. 2007;26(suppl 2):133–148

27. Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter. 2012;17:254–263

28. Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25:155–168

29. Lionetti E, Miniello VL, Castellaneta SP, et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther. 2006;24:1461–1468

30. Ziemniak W. Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol. 2006;57(suppl 3):123–141

31. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2001;15:163–169

32. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48:431–436

33. Tursi A, Brandimarte G, Giorgetti GM, et al. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit. 2004;10:CR662–CR666

34. Wang K-Y, Li S-N, Liu C-S, et al. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr. 2004;80:737–741

35. Sheu B-S, Cheng H-C, Kao A-W, et al. Pretreatment with Lactobacillus- and Bifidobacterium-containing yogurt can improve the efficacy of quadruple therapy in eradicating residual Helicobacter pylori infection after failed triple therapy. Am J Clin Nutr. 2006;83:864–869

36. Baryshnikova NV. Helicobacter pylori-associated gastroenterological diseases: genetic features and probiotic treatment. Benef Microbes. 2012;3:157–161

37. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069–1079

38. Cindoruk M, Erkan G, Karakan T, et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12:309–316

39. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010;15:206–213

40. Duman DG, Bor S, Ozütemiz O, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17:1357–1361

41. Ozdil K, Calhan T, Sahin A, et al. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology. 2011;58:1148–1152

42. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97:2744–2749

43. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2009;21:45–53

44. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter. 2008;13:261–268

45. Yoon H, Kim N, Kim JY, et al. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol. 2011;26:44–48

46. Wang Z-H, Gao Q-Y, Fang J-Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:25–32

47. Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol Clin North Am. 2006;35:355–365

48. Manfredi M, Bizzarri B, De'angelis GL. Helicobacter pylori infection: sequential therapy followed by levofloxacin-containing triple therapy provides a good cumulative eradication rate. Helicobacter. 2012;17:246–253

© 2013 Lippincott Williams & Wilkins, Inc.

Login